Korea United Pharm said it signed an export agreement to supply its osteoporosis treatment to Myanmar’s United MCK.

The export deal, announced during the Global Bio & Pharma Plaza (GBPP) 2024 event held on Tuesday to Wednesday at KINTEX located in Goyang, Gyeonggi Province, includes the supply of Bondex Injection (ingredient: ibandronate), a drug used to treat osteoporosis.

United MCKis a subsidiary of the Sakura Hospital Group, which operates three hospitals in Myanmar.

"Our partnership with United MCK highlights the competitiveness and excellence of our products in the Southeast Asian pharmaceutical market,” Korea United Pharm Managing Director Yang Jin-young siad. “ We plan to further expand our exports, including diagnostic imaging agents and other pharmaceutical products."

The deal also reflects Korea United Pharm’s ongoing global initiatives. The company has been actively involved in various international projects, including KOTRA’s (Korea Trade-Investment Promotion Agency) export voucher and overseas branch establishment programs, aiming to enhance its global reach.